Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Ribo Completes Recruitment for Phase 2a Trial of our FXI-targeting siRNA Drug
Categories: oligonucleotides
-
-
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
Kliniska studier kommer till vårdcentraler: Unikt samarbete bidrar till utvecklingen av morgondagens läkemedel
-
Advancing siRNA Drug Discovery and Development with AI
Advancing siRNA Drug Discovery and Development with AI
-
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
Ribo Advances in Cardiovascular Care with FXI Inhibiting siRNA
-
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
First milestone successfully achieved in Ribo’s collaboration on liver diseases with Boehringer Ingelheim
-
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia
Ribo's siRNA asset RBD5044 receives Clinical Trial Authorization from Swedish MPA for a Phase II trial in patients with mixed dyslipidemia.
-
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics
-
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
Ribo announces authorization to start a Phase I clinical trial in Sweden for siRNA drug RBD7007 targeting Complement Factor 5, C5
-
Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
Ribo presented the first clinical data from our completed Ph1 study of the world´s first and most advanced hemostasis-sparing antithrombotic Factor XI (FXI) targeting siRNA asset, RBD4059, based on our RIBO-GalSTAR™ technology.
-
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
Ribocure Pharmaceuticals AB announces authorization to start a Phase II clinical trial in Sweden for the worlds first siRNA drug targeting Factor XI: RBD4059
-
Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
Ribo Receives Granted Patents for Phase 2 HBV siRNA Asset RBD1016 in United States and Europe
-
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
Ribo & Ribocure successfully completed enrolment and dosing in the Phase 1 clinical trial, with world’s first siRNA drug targeting coagulation factor XI (FXI)
-
Innovating for a Healthier Tomorrow: Ribocure’s Role in Transforming Liver Disease Treatment with siRNA
Ribocure Pharmaceuticals AB announces EMA authorisation to proceed with a Phase II clinical trial in Sweden. The trial will evaluate the efficacy and safety of its novel siRNA asset RBD1016, for the treatment of the rare disease of chronic hepatitis D infection.
-
Ribocure supports RARE DISEASE DAY on February 29th
Ribocure supports RARE DISEASE DAY on February 29th
-
Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar
Ribo samarbetar med Boehringer Ingelheim för att utveckla nya behandlingar mot leversjukdomar
-
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
-
Ribo announce the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023
Ribo announce the latest research news for three siRNA therapeutic drugs at the European Society of Cardiology Congress 2023
